ME Therapeutics Holdings Inc. METXF
OTC PK
| 05/31/2026 | 02/28/2026 | 11/30/2025 | 08/31/2025 | 05/31/2025 | |
|---|---|---|---|---|---|
| Revenue | -- | -- | -- | -- | -- |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | -- | -- | -- | -- | -- |
| Cost of Revenue | -- | -- | -- | -- | -- |
| Gross Profit | -- | -- | -- | -- | -- |
| SG&A Expenses | -15.80% | -32.06% | -28.89% | -27.88% | -29.26% |
| Depreciation & Amortization | 96.27% | 252.97% | 834.21% | -- | -- |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | 30.59% | 6.47% | 0.18% | -9.02% | -18.95% |
| Operating Income | -30.59% | -6.47% | -0.18% | 9.02% | 18.95% |
| Income Before Tax | -19.45% | -1.24% | 2.84% | 9.80% | 17.06% |
| Income Tax Expenses | -- | -- | -- | -- | -- |
| Earnings from Continuing Operations | -19.45% | -1.24% | 2.84% | 9.80% | 17.06% |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | -19.45% | -1.24% | 2.84% | 9.80% | 17.06% |
| EBIT | -30.59% | -6.47% | -0.18% | 9.02% | 18.95% |
| EBITDA | -32.42% | -4.12% | 4.29% | 13.91% | 22.75% |
| EPS Basic | -6.37% | 13.64% | 16.89% | 20.67% | 34.85% |
| Normalized Basic EPS | -6.09% | 14.04% | 16.96% | 20.99% | -114.45% |
| EPS Diluted | -1.51% | 17.26% | 18.84% | 22.25% | 39.96% |
| Normalized Diluted EPS | -6.09% | 14.04% | 16.96% | 20.99% | -114.45% |
| Average Basic Shares Outstanding | 11.88% | 16.36% | 16.92% | 14.15% | 21.56% |
| Average Diluted Shares Outstanding | 11.88% | 16.36% | 16.92% | 14.15% | 21.56% |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |